I think that Minister Anand knows more about this than I do. However, I can give you a more general answer, Mr. Lemire.
Since our call to action, 6,800 companies in Canada have wanted to participate in the collective effort. What we have done is almost comparable to Project Apollo.
I want to come back to questions that were raised earlier, especially by Mr. Davies. People are wondering why some manufacturers decided to do things differently if there was a license. That's because Canada did not have the manufacturing base to produce vaccines in such large quantities. The largest factory we have is Sanofi's facility in Toronto. However, Sanofi already produces vaccines for other diseases. So that is why the contracts we have in Canada may be different.
If we take the example of AstraZeneca and India, it's important to understand that they had already established a partnership. That factory in India produces 1 billion vaccines annually. You understand that our situation is in no way comparable to India's, even if we take into account facilities we are currently building. We need to rebuild our entire manufacturing base. That explains in large part the decision made in terms of contracts.
The same goes for England. Our manufacturing base is even smaller than England's.
In these circumstances, the best solution was clearly to import vaccines, as Minister Anand decided to do. The second action we took, 12 days after the pandemic was declared, was to quickly invest considerable amounts of money to improve our manufacturing capacity in order to ensure our resilience.